PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30796464-0 2019 ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study. Platinum 51-59 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 34161330-11 2021 Our findings suggest that CHD4 mediates platinum sensitivity by modulating MDR1 expression in ovarian cancer. Platinum 40-48 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 35330134-2 2022 The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum. Platinum 216-224 ATP binding cassette subfamily B member 1 Homo sapiens 4-34 35330134-2 2022 The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum. Platinum 216-224 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 32528530-14 2020 Thus our findings suggest that inter individual variability in platinum based therapy may be anticipated by MDR1 genotypes. Platinum 63-71 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 35285843-5 2022 In addition, these novel Pt complexes reversed cisplatin-induced resistance via inhibiting the expression of P-glycoprotein and decreasing the level of glutathione in A549cisR cells. Platinum 25-27 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 34029775-4 2021 Detailed mechanisms in SGC-7901/CDDP cells assays revealed that complex 14 efficiently induced apoptosis via down-regulating expression of P-gp for enhanced intracellular uptake of platinum, arrested cells at G2/M phase, induced DNA damage and initiated mitochondrial apoptosis pathway. Platinum 181-189 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 30796464-15 2019 CONCLUSIONS: The present study reveals that ABCB1 c.3435C>T polymorphism influences platinum toxicity. Platinum 87-95 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 27590272-2 2016 Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs. Platinum 343-351 ATP binding cassette subfamily B member 1 Homo sapiens 193-198 29861877-5 2018 Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes. Platinum 269-277 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 27748801-7 2016 Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells. Platinum 28-36 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 27748801-7 2016 Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells. Platinum 28-36 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 27812204-9 2016 However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received standard platinum/paclitaxel-based chemotherapy. Platinum 153-161 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 26693899-2 2016 Re-activating BRCA1 or MDR1 mutations can underlie platinum resistance in end-stage patients. Platinum 51-59 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 24781824-7 2014 Taken together all these results strongly demonstrate that MDR-1 over-expression in A549 cells could be associated to a MDR phenotype of these cells and moreover, it is also contributing to the platinum, and structurally-related compound, resistance in these cells. Platinum 194-202 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 26288241-0 2015 Association of MDR1 gene (C3435T) polymorphism and gene expression profiling in lung cancer patients treated with platinum-based chemotherapy. Platinum 114-122 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 25253429-7 2015 Taken together, all these results strongly demonstrate that MDR-1 overexpression in K-562 cells could be associated to a MDR phenotype, and moreover, it is also contributing to the platinum and structurally related compound, resistance in these cells. Platinum 181-189 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 22766400-1 2012 We assessed whether single nucleotide polymorphisms (SNPs) in MDR1 gene C3435T predicted the outcome of platinum-based chemotherapies and survival in our non small cell lung cancer (NSCLC) patients. Platinum 104-112 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 24687344-4 2013 In regard to the clinical implications of MDR1 SNPs, it was found in large meta-analysis that C3435T SNP was associated with a slight increase in the susceptibility to ulcerative colitis and cancer and was related with slight modifications in tacrolimus pharmacokinetics and platinum-based chemotherapy response in lung cancer. Platinum 275-283 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 22833464-2 2013 Because PTCLs over express multidrug resistance gene 1/P-glycoprotein (MDR-1/P-gp), we devised platinum, etoposide, gemcitabine, and methylprednisolone (PEGS) with agents that are not substrates of the efflux pump. Platinum 95-103 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 22704851-0 2012 Role of ABCB1 C3435T in platinum-based therapy. Platinum 24-32 ATP binding cassette subfamily B member 1 Homo sapiens 8-13 22932088-10 2012 CONCLUSIONS: The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T and MDR1 C3435T SNP. Platinum 40-48 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 22932088-11 2012 In further perspective studies, the ERCC1/MDR1 SNPs might serve as simple and less invasive biomarkers for personalized chemotherapy with platinum-based anticancer drugs. Platinum 138-146 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 22761669-5 2012 MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients. Platinum 199-207 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 22112610-0 2012 Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Platinum 130-138 ATP binding cassette subfamily B member 1 Homo sapiens 19-24 19516889-10 2009 The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis. Platinum 119-127 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 21827803-0 2011 Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Platinum 71-79 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 21827803-2 2011 We performed this meta-analysis to compare outcome to platinum-based chemotherapies in advanced non-small cell lung cancer (NSCLC) with different ERCC1 C118T/C8092A and MDR1 C3435T polymorphisms. Platinum 54-62 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 22296372-0 2011 Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Platinum 62-70 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 22296372-1 2011 OBJECTIVE: To evaluate the influence of multi-drug resistance 1 (MDR1) gene codon 3435 polymorphisms on response to platinum-based chemotherapeutic regimens for advanced non small cell lung cancer (NSCLC). Platinum 116-124 ATP binding cassette subfamily B member 1 Homo sapiens 40-63 22296372-1 2011 OBJECTIVE: To evaluate the influence of multi-drug resistance 1 (MDR1) gene codon 3435 polymorphisms on response to platinum-based chemotherapeutic regimens for advanced non small cell lung cancer (NSCLC). Platinum 116-124 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 22296372-7 2011 CONCLUSION: Our research suggested that patents with the C/C genotype in MDR1 codon 3435 could be more sensitive to platinum-based chemotherapy than patients with C/T and T/T; however, no significant difference was found between overall survival and MDR1 codon 3435 genetic polymorphisms. Platinum 116-124 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 22296372-7 2011 CONCLUSION: Our research suggested that patents with the C/C genotype in MDR1 codon 3435 could be more sensitive to platinum-based chemotherapy than patients with C/T and T/T; however, no significant difference was found between overall survival and MDR1 codon 3435 genetic polymorphisms. Platinum 116-124 ATP binding cassette subfamily B member 1 Homo sapiens 250-254 20189873-11 2010 Our results suggested that gene polymorphisms in MDR1G2677T/A may be a predictive marker of platinum-based treatment response and of secondary effects, especially gastrointestinal toxicity for advanced NSCLC patients. Platinum 92-100 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 19516889-10 2009 The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis. Platinum 119-127 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 18281754-3 2008 Na(+), K(+)-ATPase and multidrug resistance protein 1 were reported to be related to the accumulation of platinum drugs in tumor cells. Platinum 105-113 ATP binding cassette subfamily B member 1 Homo sapiens 23-53 11878288-5 2001 We investigated the relation between P-glycoprotein and glutation S-transferase level for response to platinum-based chemotherapy in epithelial ovarian cancer. Platinum 102-110 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 17686239-12 2007 CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer. Platinum 95-103 ATP binding cassette subfamily B member 1 Homo sapiens 37-40 16785472-6 2006 For patients receiving platinum drugs, the MDR1 C3435T variant allele was associated with significantly reduced recurrence risk (HR = 0.25; 95% CI, 0.10 to 0.64) and improved survival (HR = 0.44; 95% CI, 0.23 to 0.85). Platinum 23-31 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 11809106-6 2000 The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P < 0.05). Platinum 22-30 ATP binding cassette subfamily B member 1 Homo sapiens 98-102